These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12111188)

  • 21. Hyperprolactinaemia does not always mean 'hyperprolactinaemia'!
    Gezer A; Atasü T; Hekim C; Stenman UH; Hekim N
    Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):206-8. PubMed ID: 15653204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Macroprolactin-a cause of pseudohyperprolactinaemia.
    Yuen YP; Lai JP; Au KM; Chan AY; Mak TW
    Hong Kong Med J; 2003 Apr; 9(2):119-21. PubMed ID: 12668823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of prolactin: the macroprolactin problem.
    Fahie-Wilson M; Smith TP
    Best Pract Res Clin Endocrinol Metab; 2013 Oct; 27(5):725-42. PubMed ID: 24094642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid detection of macroprolactin in the form of prolactin-immunoglobulin G complexes by immunoprecipitation with anti-human IgG-agarose.
    Schiettecatte J; De Schepper J; Velkeniers B; Smitz J; Van Steirteghem A
    Clin Chem Lab Med; 2001 Dec; 39(12):1244-8. PubMed ID: 11798085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases.
    Neidhart M
    J Rheumatol; 1996 Mar; 23(3):476-81. PubMed ID: 8832986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macroprolactinemia: clinical significance and characterization of the condition.
    Theunissen C; De Schepper J; Schiettecatte J; Verdood P; Hooghe-Peeters EL; Velkeniers B
    Acta Clin Belg; 2005; 60(4):190-7. PubMed ID: 16279400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition.
    Olukoga AO; Kane JW
    Clin Endocrinol (Oxf); 1999 Jul; 51(1):119-26. PubMed ID: 10468974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roche Elecsys Prolactin II assay: reactivity with macroprolactin compared with eight commercial assays for prolactin and determination of monomeric prolactin by precipitation with polyethylene glycol.
    Fahie-Wilson M; Bieglmayer C; Kratzsch J; Nusbaumer C; Roth HJ; Zaninotto M; Plebani M; Hubbuch A; Schneider E
    Clin Lab; 2007; 53(5-6):301-7. PubMed ID: 17605405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for macroprolactinaemia.
    Olukoga AO; Kane J
    Ann Clin Biochem; 1997 Nov; 34 ( Pt 6)():701-3; author reply 703-4. PubMed ID: 9367016
    [No Abstract]   [Full Text] [Related]  

  • 30. [The value of functional tests in diagnosis of prolactinoma].
    Klockenbusch W; Distler W; von Ditfurth M; Graf M; Jahn K
    Geburtshilfe Frauenheilkd; 1990 May; 50(5):383-7. PubMed ID: 2115483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The natural history of macroprolactinaemia.
    Hattori N; Adachi T; Ishihara T; Shimatsu A
    Eur J Endocrinol; 2012 Apr; 166(4):625-9. PubMed ID: 22247016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macroprolactinaemia, the major unknown in the differential diagnosis of hyperprolactinaemia.
    Cattaneo F; Kappeler D; Müller B
    Swiss Med Wkly; 2001 Mar; 131(9-10):122-6. PubMed ID: 11416967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia.
    Hattori N; Nakayama Y; Kitagawa K; Ishihara T; Saiki Y; Inagaki C
    J Endocrinol; 2006 Aug; 190(2):287-93. PubMed ID: 16899562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia.
    Poyraz BC; Aksoy C; Balcioğlu I
    Eur Neuropsychopharmacol; 2008 Sep; 18(9):667-72. PubMed ID: 18539008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperprolactinemia in clinically asymptomatic, fertile men: report of two cases.
    Colon JM; Ginsburg F; Schmidt CL; Weiss G
    Obstet Gynecol; 1989 Sep; 74(3 Pt 2):510-3. PubMed ID: 2503796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
    Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
    Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pituitary imaging is indicated for the evaluation of hyperprolactinemia.
    Bayrak A; Saadat P; Mor E; Chong L; Paulson RJ; Sokol RZ
    Fertil Steril; 2005 Jul; 84(1):181-5. PubMed ID: 16009175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of raised levels of IL-4 and anti-TPO with hyperprolactinemia.
    Kalsi AK; Halder A; Jain M; Chaturvedi PK; Mathew M; Sharma JB
    Am J Reprod Immunol; 2019 Mar; 81(3):e13085. PubMed ID: 30614113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of autoantibodies and immunoglobulin G subclasses in women with suspected macroprolactinemia.
    Yu C; Fan F; Hu S; Meng L; Xu D; Wang J; Chen L; Liu J; Dong Y; Lu Y; Shen M; Zhai Y; Cao Z
    J Clin Lab Anal; 2020 Nov; 34(11):e23456. PubMed ID: 32597541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macroprolactin: what is it and what is its importance?
    Sadideen H; Swaminathan R
    Int J Clin Pract; 2006 Apr; 60(4):457-61. PubMed ID: 16620360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.